Nov 27 (Reuters) - Orange (ORAN.PA), opens new tab has struck a multi-year partnership with OpenAI in Europe that will give the French telecoms operator access to pre-release AI models ...

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

Orange stools can be caused by foods that are orange in color (either natural or artificial color, which tends to last much longer and have deeper color). Orange poop can also happen after taking ...

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock opportunity. I think the global biopharma company has been dripping with promise ...

From 19 to 21 November 2024 at the Porte de Versailles, Orange welcomes you to our stand A11, Pavilion 4, or to the conferences we’re hosting, to discover more about smart cities ... The French copper ...

The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock undervalued right now. When investing, your capital is at risk.

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ...

GSK’s (LSE: GSK) share price is down 28% from its 15 May 12-month traded high of £18.19. As a shareholder, this raises the question of whether I should sell, keep what I have, or buy more. In my ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...

GSK stock remains in a deep bear market, falling by 27% from the year-to-date high. The company made strong progress on its linerixibat trial. There are concerns about Robert Kennedy Jr ...